Please assess the completion status of the following clinical trial:

Trial Title: Urticaria Facticia Treatment With Omalizumab (UFO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18-75 years)~* Informed consent signed and dated~* Able to read, understand and willing to sign the informed consent form and abide with study procedures~* Diagnosis of UF lasting for at least 6 months~* Willing, committed and able to return for all clinic visits and complete all study-related procedures, including willingness to have SC injections administered by a qualified person~* In females of childbearing potential: Negative pregnancy test; females willing to use highly effective contraception (Pearl-Index \< 1). A woman will be considered not of childbearing potential if she is post-menopausal for greater than two years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)~* No participation in other clinical trials 4 weeks before and after participation in this study~Exclusion Criteria:~* Patients with acute urticaria~* Concurrent/ongoing treatment with immunosuppressives (e.g. systemic steroids, cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to day 0, whichever is longer~* Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial~* Significant concomitant illness that would adversely affect the subject's participation or evaluation in this study~* History of malignancies within five years prior to screening other than a successfully treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ cancer~* Presence of clinically significant laboratory abnormalities~* Lactating females or pregnant females~* Subjects for whom there is concern about compliance with the protocol procedures~* Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk~* History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) within the last 5 years that could limit the subject's ability to comply with study procedures~* Subjects who are detained officially or legally to an official institute~* Previous use of omalizumab within the last 6 months~* Intake of antihistamines or leukotriene antagonists within 4 days prior to visit 1~* Intake of oral corticosteroids within 14 days prior to visit 1~* Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study~* Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omalizumab 150mg (Type: EXPERIMENTAL): None
- Omalizumab 300mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete